C4 Therapeutics (CCCC) Short term Debt (2022 - 2023)
C4 Therapeutics' quarterly Short term Debt came in at $10.3 million in Q2 2023, up 1278.0% year-on-year from $750000.0 in Q2 2022, and up 351.9% quarter-over-quarter from $2.3 million in Q1 2023.
C4 Therapeutics has reported Short term Debt for 2 years, with the latest figure at $10.3 million in Q2 2023.
- For the quarter ending Q2 2023, Short term Debt rose 1278.0% year-over-year to $10.3 million; the trailing twelve-month figure through Jun 2023 stood at $10.3 million (up 1278.0% YoY), and the FY2022 full-year result was $2.3 million, changed N/A from the prior year.
- Short term Debt for Q2 2023 stood at $10.3 million, up from $2.3 million in the prior quarter.
- The five-year high for Short term Debt was $10.3 million in Q2 2023, with the low at $750000.0 in Q1 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | C4 Therapeutics | 561.03 Mn | 325.36 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 10.34 Mn |
| Mar 31, 2023 | 2.29 Mn |
| Dec 31, 2022 | 2.29 Mn |
| Sep 30, 2022 | 2.25 Mn |
| Jun 30, 2022 | 750,000.00 |
| Mar 31, 2022 | 750,000.00 |